AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesInformation ScienceNamed GroupsHealth CareGeographicals
HIV SeropositivityHIV SeroprevalenceHIV InfectionsSubstance Abuse, IntravenousSexual BehaviorRisk FactorsDisease ProgressionSeroepidemiologic StudiesCell DeathCause of DeathEndpoint DeterminationAntibodies, ViralAntibodies, BacterialChlamydophila pneumoniaeImmunoglobulin GDeathChlamydophila InfectionsEnzyme-Linked Immunosorbent AssaySerologic TestsTreatment OutcomePrevalenceTime FactorsHIV SeronegativityProspective StudiesFollow-Up StudiesHelicobacter pyloriHelicobacter InfectionsAcquired Immunodeficiency SyndromeCohort StudiesHIV-1ToxocariasisAntibodies, ProtozoanCytomegalovirus InfectionsAge FactorsCross-Sectional StudiesRetrospective StudiesCase-Control StudiesDeath, Sudden, CardiacToxoplasmosisHepatitis CHerpesvirus 2, HumanPrognosisToxocaraAIDS SerodiagnosisIncidencePapillomavirus InfectionsCD4 Lymphocyte CountBlood DonorsOdds RatioMultivariate AnalysisBiological MarkersRural PopulationBrazilCell CycleCell Line, TumorNeosporaCytomegalovirusLogistic ModelsUnited StatesBrain DeathSurvival AnalysisHerpes GenitalisAnti-HIV AgentsSyphilisImmunoglobulin AToxoplasmaHuman papillomavirus 16Viral LoadHomosexualityRisk AssessmentImmunoglobulin MApoptosisPregnancyHomosexuality, MaleHepatitis A Virus, HumanKaplan-Meier Estimate
EfficacyAIDSInfectionMortalityInfectionsAntibodiesAntiretroviral therapyPreventionGeneProteinPatientsPrimaryComplicationsVirusesSurvivalTreatmentHumanTransmissionSubjectsApproximatelyDevelopmentCommonCasesHeartTuberculosisIncidencePneumoniaMechanical ventilationVaccineDiagnosisTherapyEarlyDiseaseStudyRiskPeopleComplete
Efficacy4
  • Results Thirty one patients received at least 1 dose of study treatment and 30 were assessable for efficacy endpoints. (bmj.com)
  • Rationale: We developed a standardized method, possible poor treatment response (PPTR), to help ascertain efficacy endpoints in Study S31/A5349 (NCT02410772), an open-label trial comparing two 4-month rifapentine-based regimens with a standard 6-month regimen for the treatment of pulmonary tuberculosis (TB). (cdc.gov)
  • Objectives: We describe the use of the PPTR process and evaluate whether the goals of minimizing bias in efficacy endpoint assessment and attainment of relevant data to determine outcomes for all participants were achieved. (cdc.gov)
  • A separate analysis of the FINCH 2 trial assessed the efficacy of once-daily filgotinib 200 mg or 100 mg versus placebo for 24 weeks across prespecified subgroup characteristics such as disease duration/activity, seropositivity and concurrent medication use. (gilead.com)
AIDS9
  • This course is designed for all behavioral health professionals, including social workers, counselors, and marriage and family therapists, who may be involved with the care of persons with HIV or AIDS. (netce.com)
  • Sendai virus is used as a backbone for vaccine development against Mycobacterium tuberculosis that causes tuberculosis, against HIV-1 that causes AIDS and against other viruses, including those that cause severe respiratory infections in children. (wikipedia.org)
  • One study of nearly 7000 men with HIV infection found that annual mortality rates decreased from 7% in 1996 to 1.3% in 2004, although the findings highlighted the fact that non-AIDS-related illnesses were accounting for a greater proportion of deaths. (medscape.com)
  • [ 112 ] which showed that cancers as a cause of mortality decreased overall but increased as a percentage of deaths, with non-Hodgkin lymphoma being the most common AIDS-related cancer and lung cancer being the most common non-AIDS-related cancer. (medscape.com)
  • A National Cancer Institute study attributed increased non-AIDS-defining cancer mortality to the 4-fold expansion in the HIV-infected population in the United States, which was largely driven by greater numbers of people aged 40 years and older. (medscape.com)
  • FINDINGS: 25(OH)D deficiency is a ubiquitous condition associated with multiple nonskeletal diseases, including cardiometabolic (heart disease, diabetes, and kidney disease), immune (HIV/AIDS and cancer), lung (from traditional chronic disorders to coronavirus disease 2019), and gut diseases. (bvsalud.org)
  • Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. (lookformedical.com)
  • The Council for International Organizations of Medical Sciences (CIOMS) acknowledges the substantial financial contribution of the Joint United Nations Programme on HIV/AIDS (UNAIDS) to the preparation of the 2002 International Ethical Guidelines for Biomedical Research Involving Human Subjects . (unibuc.ro)
  • The World Health Organization in Geneva contributed generously also through the departments of Reproductive Health and Research, Essential Drugs and Medicines Policy, Vaccines and Biologicals, and HIV/AIDS/Sexually Transmitted Infections, as well as the Special Programme for Research and Training in Tropical Diseases. (unibuc.ro)
Infection9
  • The primary clinical end point was the earliest occurrence of pulmonary tuberculosis, severe bacterial infection, a World Health Organization stage 4 event, or death. (nih.gov)
  • ACIP recommends vaccination of men who have sex with men and immunocompromised persons (including those with HIV infection) through age 26 years if not previously vaccinated. (cdc.gov)
  • Behavioral health professionals will continue to play a major and significant role in preventing the spread of HIV infection and in caring for those who are infected or affected by HIV. (netce.com)
  • As the demographics of HIV infection evolve, both in the United States and around the world, it is clear that all healthcare professionals in all practice settings will be involved to some extent with HIV infection. (netce.com)
  • Treatment guidelines for HIV infection are age-specific. (medscape.com)
  • guidelines for adults and adolescents are compiled by the Panel on Clinical Practices for Treatment of HIV Infection. (medscape.com)
  • For discussion of antiretroviral drugs and regimens, see Antiretroviral Therapy for HIV Infection . (medscape.com)
  • The Infectious Diseases Society of America (IDSA) issued updated guidelines in November 2021 for the management of HIV infection. (medscape.com)
  • Nineteen patients (9.1%) had HIV infection, 45 (21.6%) had diabetes mellitus, 30 (14.4%) had chronic renal failure, 12 (5.7%) had cirrhosis, 7 (3.3%) had malignancy, and 21 (10.1%) had a history of immunosuppressive medication use. (bvsalud.org)
Mortality2
  • The secondary outcome results in favour of IFX-1 are preliminary because the study was not powered on these endpoints, but they support the investigation of C5a inhibition with IFX-1 in a phase 3 trial using 28-day mortality as the primary endpoint.FundingInflaRx. (tropmedres.ac)
  • The primary endpoint was all-cause in-hospital mortality. (ox.ac.uk)
Infections3
Antibodies2
  • Antibodies reactive with HIV ANTIGENS . (lookformedical.com)
  • Progression to wheelchair dependence was faster among patients with paraneoplastic compared with nonparaneoplastic autoimmune ataxia and among those with positivity for neuronal nuclear and cytoplasmic antibodies (NNC Abs + ) only (vs positivity for plasma membrane protein Abs [PMP Abs + ] only). (jamanetwork.com)
Antiretroviral therapy3
  • Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. (nih.gov)
  • HIV-1-infected subjects with CD4 counts between 350 and 550 cells per cubic millimeter were randomly assigned in a 1:1 ratio to receive antiretroviral therapy either immediately (early therapy) or after a decline in the CD4 count or the onset of HIV-1-related symptoms (delayed therapy). (nih.gov)
  • The early initiation of antiretroviral therapy reduced rates of sexual transmission of HIV-1 and clinical events, indicating both personal and public health benefits from such therapy. (nih.gov)
Prevention2
  • The primary prevention end point was linked HIV-1 transmission in HIV-1-negative partners. (nih.gov)
  • To be effective and provide compassionate care, adequate and up-to-date information about transmission, prevention, and care of HIV-infected individuals must be obtained by all behavioral health professionals. (netce.com)
Gene2
  • External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. (lookformedical.com)
  • Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. (lookformedical.com)
Protein3
  • Seropositivity to the early transcribed membrane protein 5 antigen 1 represented recent exposure to P. falciparum. (cdc.gov)
  • It serves as a precursor for both the HIV ENVELOPE PROTEIN GP120 and the HIV ENVELOPE PROTEIN GP41 . (lookformedical.com)
  • Patients with GAD65 seropositivity and patients with plasma membrane protein (PMP) seropositivity progressed to wheelchair dependence at similar rates. (jamanetwork.com)
Patients2
  • A total of 34 (16.3%) patients died and death was attributable to TBP in all cases. (bvsalud.org)
  • Progression to wheelchair dependence was faster among patients with Purkinje cell cytoplasmic antibody type 1 (PCA-1) seropositivity and glutamic acid decarboxylase 65-kDa autoantibody (GAD65) seronegativity. (jamanetwork.com)
Primary2
  • The primary endpoint was blood-stage P. falciparum parasitaemia of ≥500/μl while the secondary endpoint was the receipt of antimalarial treatment in the presence of parasitaemia of any density. (ox.ac.uk)
  • On study completion, all participants were genotyped both for Dantu and for four other polymorphisms that are associated with protection against severe falciparum malaria: α+-thalassaemia, blood group O, G6PD deficiency, and the rs4951074 allele in the red cell calcium transporter ATP2B4.ResultsThe primary endpoint was reached in 25/111 (22.5%) non-Dantu subjects in comparison to 0/27 (0%) Dantu heterozygotes and 0/3 (0.0%) Dantu homozygotes (p=0.01). (ox.ac.uk)
Complications1
Viruses1
Survival1
  • Median progression-free survival was 5.9 months. (bmj.com)
Treatment1
  • The frequency of serious adverse events were similar between groups (nine [60%] in the IFX-1 group vs seven [47%] in the control group) and no deaths were considered related to treatment assignment. (tropmedres.ac)
Human1
  • BackgroundThe long co-evolution of Homo sapiens and Plasmodium falciparum has resulted in the selection of numerous human genetic variants that confer an advantage against severe malaria and death. (ox.ac.uk)
Transmission2
  • Since the discovery of HIV, scientists have made major inroads in understanding modes of transmission, infectivity, and pathogenicity. (netce.com)
  • Although multifactorial in nature (transmission mode and patient educational level are independent risk factors for these events) there may also be a direct role of HIV in these events, or an indirect role mediated through the subsequent immune dysfunction. (medscape.com)
Subjects1
  • Similarly, 49/111 (44.1%) non-Dantu subjects reached the secondary endpoint in comparison to only 7/27 (25.9%) and 0/3 (0.0%) Dantu heterozygotes and homozygotes, respectively (p=0.021). (ox.ac.uk)
Approximately1
  • Approximately 8,500 cases were reported and at least 916 deaths ( 1 ). (cdc.gov)
Development1
  • A SeV-based vaccine development against HIV-1 has reached a phase II clinical trial. (wikipedia.org)
Common1
  • Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING. (lookformedical.com)
Cases1
  • An additional 237 cases were identified and 33 deaths. (cdc.gov)
Heart1
Tuberculosis2
  • The primary clinical end point was the earliest occurrence of pulmonary tuberculosis, severe bacterial infection, a World Health Organization stage 4 event, or death. (nih.gov)
  • Sendai virus is used as a backbone for vaccine development against Mycobacterium tuberculosis that causes tuberculosis, against HIV-1 that causes AIDS and against other viruses, including those that cause severe respiratory infections in children. (wikipedia.org)
Incidence1
  • The incidence of CMV seropositivity rises with age and in a US-based study was reported to increase from 36% in children aged 6-11 years to 91% in individuals older than 80 years. (medscape.com)
Pneumonia1
  • severe COVID-19 often involves progressive respiratory failure and may also result in life-threatening pneumonia, multiorgan failure, and death [ 2 , 3 ]. (nih.gov)
Mechanical ventilation1
  • With the exception of rituximab (HR 1.72, 1.10-2.69), there was no increased risk of mechanical ventilation or in-hospital death for the rheumatological, antineoplastic, or antimetabolite therapies examined. (covidreference.com)
Vaccine3
  • A SeV-based vaccine development against HIV-1 has reached a phase II clinical trial. (wikipedia.org)
  • The methods followed by SAGE2 and the sont publiés en même temps que la note de processes3 for preparation of vaccine posi- synthèse. (who.int)
  • 2017 (www.who.int/publications/m/item/guidance-for-the-de- (www.who.int/publications/m/item/guidance-for-the-development- velopment-of-evidence-based-vaccine-related-recommenda- of-evidence-based-vaccine-related-recommendations, consulté en tions, accessed August 2022). (who.int)
Diagnosis1
Therapy1
Early1
  • Seropositivity to the early transcribed membrane protein 5 antigen 1 represented recent exposure to P. falciparum. (cdc.gov)
Disease2
  • The treatment of human immunodeficiency virus (HIV) disease depends on the stage of the disease and any concomitant opportunistic infections. (medscape.com)
  • This condition increases disease severity and risk of death, so tempering the body's inflammatory response is an important component of COVID-19 management. (nih.gov)
Study1
  • As part of the fourth round of study with an urban African-American community cohort, the following investigation was aimed at assessing HIV-1 prevalence and the relative. (lookformedical.com)
Risk2
  • Although multifactorial in nature (transmission mode and patient educational level are independent risk factors for these events) there may also be a direct role of HIV in these events, or an indirect role mediated through the subsequent immune dysfunction. (medscape.com)
  • HIV-1 seroprevalence and risk behaviors in an urban African-American Community cohort. (lookformedical.com)
People2
  • People living with HIV have been excluded from these studies. (bvsalud.org)
  • INTERPRETATION: Brentuximab vedotin-AVD was highly active and had a tolerable adverse event rate in HIV-cHL and is an important therapeutic option for people with HIV-cHL. (bvsalud.org)
Complete1
  • The complete reponse rate is encouraging and is possibly related to a unique aspect of HIV-cHL biology. (bvsalud.org)